Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 11/2023

Open Access 13-07-2023 | Pathology | Review Article

Salivary gland pathologies: evolution in classification and association with unique genetic alterations

Authors: Michał Żurek, Łukasz Fus, Kazimierz Niemczyk, Anna Rzepakowska

Published in: European Archives of Oto-Rhino-Laryngology | Issue 11/2023

Login to get access

Abstract

Purpose

The correct classification of salivary gland pathologies is crucial for choosing a treatment method and determining the prognosis. Better outcomes are now achievable thanks to the introduction of new therapy approaches, such as targeted therapies for malignant salivary gland tumors. To apply these in clinical routine, a clear classification of the lesions is required.

Methods

The following review examines all changes from the first World Health Organization (WHO) Classification of salivary gland pathologies from 1972 to fifth edition from 2022. Possible developments in the diagnosis and classification of salivary gland pathology are also presented.

Results

The current WHO classification is the fifth edition. With the development of new diagnostic methods, based on genetic alterations, it provides insight into the molecular basis of lesions. This has resulted in the evolution of classification, introduction of new entities and reclassification of existing ones.

Conclusions

Genetic alterations will become increasingly more significant in the identification of salivary gland pathologies in the future. These alterations will be helpful as prognostic and predictive biomarkers, and may also serve as targets for anti-cancer therapies.
Literature
1.
Thackray AC, Sobin LH (1972) Histological typing of salivary gland tumours. In: World Health Organization. International histological classification of tumours. Geneva: The Organization
2.
Seifert G, Sobin LH (1991) Histological typing of salivary gland tumours. In: World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag
3.
Barnes L, Eveson JW, Reichart P, Sidransky D (2005) World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. 3rd Edition. Lyon: IARC
4.
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg P (2017) WHO classification of head and neck tumours. 4th Edition. Lyon: IARC
5.
WHO Classififcation of Tumours Editorial Board (2022) Head and Neck tumours. WHO classification of tumours series. 5th Edition. Lyon: IARC
6.
Mueller SK et al (2022) Targeted therapy, chemotherapy, immunotherapy and novel treatment options for different subtypes of salivary gland cancer. J Clin Med 11(3):720PubMedPubMedCentralCrossRef
7.
Seifert G, Sobin LH (1992) The World Health Organization's histological classification of salivary gland tumors. a commentary on the second edition. Cancer 70(2): 379–385
8.
Rooper LM et al (2021) Salivary mucinous adenocarcinoma is a histologically diverse single entity with recurrent AKT1 E17K mutations: clinicopathologic and molecular characterization with proposal for a unified classification. Am J Surg Pathol 45(10):1337–1347PubMedCrossRef
9.
Nakaguro M et al (2022) NKX3.1 expression in salivary gland “Intraductal” papillary mucinous neoplasm: a low-grade subtype of salivary gland mucinous adenocarcinoma. Head Neck Pathol 16(4):1114–1123PubMedPubMedCentralCrossRef
10.
Agaimy A et al (2018) Intraductal papillary mucinous neoplasms of minor salivary glands with AKT1 pGlu17Lys mutation. Am J Surg Pathol 42(8):1076–1082PubMedCrossRef
11.
Skalova A, Hyrcza MD, Leivo I (2022) Update from the 5th Edition of the World Health Organization classification of head and neck tumors: salivary glands. Head Neck Pathol 16(1): 40–53
12.
Skalova A et al (2019) NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is “Intraductal” correct? Am J Surg Pathol 43(10):1303–1313PubMedCrossRef
13.
Bishop JA et al (2021) The myoepithelial cells of salivary intercalated duct-type intraductal carcinoma are neoplastic: a study using combined whole-slide imaging, immunofluorescence, and RET fluorescence in situ hybridization. Am J Surg Pathol 45(4):507–515PubMedCrossRef
14.
Toper MH, Sarioglu S (2021) Molecular pathology of salivary gland neoplasms: diagnostic, prognostic, and predictive perspective. Adv Anat Pathol 28(2):81–93PubMedCrossRef
15.
Skalova A et al (2022) Fusion-positive salivary gland carcinomas. Genes Chromosomes Cancer 61(5):228–243PubMedCrossRef
16.
Seethala RR (2013) Oncocytic and apocrine epithelial myoepithelial carcinoma: novel variants of a challenging tumor. Head Neck Pathol 7(Suppl 1):S77-84PubMedCrossRef
17.
18.
Tahiri I et al (2022) Squamous cell carcinoma of the submandibular gland with cutaneous fistula: a case report and literature review. Cureus 14(8):e27785PubMedPubMedCentral
19.
Jo U et al (2020) Primary squamous cell carcinoma of the salivary gland: immunohistochemical analysis and comparison with metastatic squamous cell carcinoma. J Pathol Transl Med 54(6):489–496PubMedPubMedCentralCrossRef
20.
Andreasen S et al (2019) An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. APMIS 127(5):240–264PubMedCrossRef
21.
Eveson JW, Cawson RA (1986) Warthin’s tumor (cystadenolymphoma) of salivary glands. A clinicopathologic investigation of 278 cases. Oral Surg Oral Med Oral Pathol 61(3):256–262PubMedCrossRef
22.
23.
24.
Califano J, Eisele DW (1999) Benign salivary gland neoplasms. Otolaryngol Clin North Am 32(5):861–873PubMedCrossRef
25.
Franzen AM et al (2018) Increased incidence of Warthin tumours of the parotid gland: a 42-year evaluation. Eur Arch Otorhinolaryngol 275(10):2593–2598PubMedCrossRef
26.
Saravakos P et al (2022) Parotid gland tumors: a multicenter analysis of 1020 cases. Increasing incidence of Warthin’s Tumor. Indian J Otolaryngol Head Neck Surg 74(Suppl 2):2033–2040PubMedCrossRef
27.
Yanes-Diaz J et al (2023) Trend changes in the incidence of benign parotid tumours in the last 30 years in a Spanish population. Eur Arch Otorhinolaryngol 280(2):855–860PubMedCrossRef
28.
29.
Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23(9):705–712PubMedCrossRef
30.
Knight J, Ratnasingham K (2015) Metastasising pleomorphic adenoma: Systematic review. Int J Surg 19:137–145PubMedCrossRef
31.
Bradley PJ (2005) “Metastasizing pleomorphic salivary adenoma” should now be considered a low-grade malignancy with a lethal potential. Curr Opin Otolaryngol Head Neck Surg 13(2):123–126PubMedCrossRef
32.
Seethala RR, Stenman G (2017) Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland. Head Neck Pathol 11(1): 55–67
33.
Bishop JA et al (2020) Sclerosing polycystic “Adenosis” of salivary glands: a neoplasm characterized by PI3K pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol 14(3):630–636PubMedCrossRef
34.
35.
Hernandez-Prera JC et al (2022) Sclerosing polycystic adenoma: conclusive clinical and molecular evidence of its neoplastic nature. Head Neck Pathol 16(2):416–426PubMedCrossRef
36.
Canas Marques R, Felix A (2014) Invasive carcinoma arising from sclerosing polycystic adenosis of the salivary gland. Virchows Arch 464(5):621–625PubMedCrossRef
37.
Seifert G, Bull HG, Donath K (1980) Histologic subclassification of the cystadenolymphoma of the parotid gland. Analysis of 275 cases. Virchows Arch A Pathol Anat Histol 388(1):13–38PubMedCrossRef
38.
Abbondanzo SL (2001) Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol 5(4):246–254PubMedCrossRef
39.
Smith BC et al (1996) Sclerosing polycystic adenosis of major salivary glands. A clinicopathologic analysis of nine cases. Am J Surg Pathol 20(2):161–170PubMedCrossRef
40.
Gnepp DR (2014) Salivary gland tumor “wishes” to add to the next WHO Tumor Classification: sclerosing polycystic adenosis, mammary analogue secretory carcinoma, cribriform adenocarcinoma of the tongue and other sites, and mucinous variant of myoepithelioma. Head Neck Pathol 8(1):42–49PubMedPubMedCentralCrossRef
41.
42.
Psychogios G et al (2021) Review of surgical techniques and guide for decision making in the treatment of benign parotid tumors. Eur Arch Otorhinolaryngol 278(1):15–29PubMedCrossRef
43.
Lombardi D et al (2022) Parotid pleomorphic and non-pleomorphic adenomas: a mono-institutional series of 512 patients. Eur Arch Otorhinolaryngol 279(5):2543–2551PubMedCrossRef
44.
Thompson LD et al (2015) Canalicular adenoma: a clinicopathologic and immunohistochemical analysis of 67 cases with a review of the literature. Head Neck Pathol 9(2):181–195PubMedCrossRef
45.
Petersson F (2013) Sclerosing polycystic adenosis of salivary glands: a review with some emphasis on intraductal epithelial proliferations. Head Neck Pathol 7 Suppl 1(Suppl 1): S97–106
46.
Skalova A et al (2022) Sclerosing polycystic adenoma of salivary glands: a novel neoplasm characterized by PI3K-AKT pathway alterations-new insights into a challenging entity. Am J Surg Pathol 46(2):268–280PubMedCrossRef
47.
Caudell JJ et al. (2022) NCCN Guidelines(R) Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw 20(3):224–234
48.
Ferrell JK, Mace JC, Clayburgh D (2019) Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review. Eur Arch Otorhinolaryngol 276(4):1135–1146PubMedCrossRef
49.
Zurek M et al (2022) Clinico-epidemiological analysis of most prevalent parotid gland carcinomas in poland over a 20-year period. Int J Environ Res Public Health 19(16):10247PubMedPubMedCentralCrossRef
50.
Terhaard CH et al (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26(8):681–692PubMedCrossRef
51.
Kordzinska-Cisek I, Cisek P, Grzybowska-Szatkowska L (2020) The role of prognostic factors in salivary gland tumors treated by surgery and adjuvant radio- or chemoradiotherapy - a single institution experience. Cancer Manag Res 12:1047–1067PubMedPubMedCentralCrossRef
52.
Oliveira LR et al (2011) Prognostic factors in patients with malignant salivary gland neoplasms in a Brazilian population. Asian Pac J Cancer Prev 12(2):363–368PubMed
53.
Yamada SI et al (2018) Significant prognostic factors affecting treatment outcomes of salivary gland carcinoma: a multicenter retrospective analysis. Odontology 106(1):96–102PubMedCrossRef
54.
Farhood Z, Zhan KY, Lentsch EJ (2016) Mucinous adenocarcinoma of the salivary gland: a review of a rare tumor. Otolaryngol Head Neck Surg 154(5):875–879PubMedCrossRef
55.
Rooper LM (2021) Emerging entities in salivary pathology: a practical review of sclerosing microcystic adenocarcinoma, microsecretory adenocarcinoma, and secretory myoepithelial carcinoma. Surg Pathol Clin 14(1):137–150PubMedCrossRef
56.
Ide F et al (2009) Mucinous adenocarcinoma of minor salivary glands: a high-grade malignancy prone to lymph node metastasis. Virchows Arch 454(1):55–60PubMedCrossRef
57.
Pham T et al (2019) First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). Contemp Clin Trials Commun 16:100409PubMedPubMedCentralCrossRef
58.
Ferrarotto R et al (2018) A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 29(7):1561–1568PubMedCrossRef
59.
Ferrarotto R et al (2020) 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Ann Oncol 31:S663CrossRef
60.
van Boxtel W et al (2020) (68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics 10(5):2273–2283PubMedPubMedCentralCrossRef
61.
Takase S et al (2017) Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 8(35):59023–59035PubMedPubMedCentralCrossRef
62.
Fushimi C et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29(4):979–984PubMedCrossRef
63.
Jhaveri KL et al (2019) Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 30(11):1821–1830PubMedPubMedCentralCrossRef
64.
Stenman G (2013) Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 7(Suppl 1):S12–S19PubMedCrossRef
65.
Pouloudi D et al (2021) Clinical significance of histone deacetylase (HDAC)-1, -2, -4 and -6 expression in salivary gland tumors. Diagnostics (Basel) 11(3):517PubMedCrossRef
66.
Theocharis S et al (2020) Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment? Expert Opin Ther Targets 24(10):1047–1059PubMedCrossRef
67.
Daneshbod Y, Daneshbod K, Khademi B (2009) Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited. Acta Cytol 53(1):53–70PubMedCrossRef
68.
Faquin WCRED (2018) Milan system for reporting salivary gland cytopathology. Springer International Publishing
69.
Archondakis S, Roma M, Kaladelfou E (2021) Two-year experience of the implementation of the Milan for reporting salivary gland cytopathology at a private medical laboratory. Head Neck Pathol 15(3):780–786PubMedPubMedCentralCrossRef
70.
Alwagdani A et al (2021) Role of fine needle aspiration in malignant parotid tumors at a single-center experience: a retrospective cohort study. Ann Med Surg (Lond) 64:102229PubMed
71.
Cho J et al (2020) Comparison of core needle biopsy and fine-needle aspiration in diagnosis of malignant salivary gland neoplasm: systematic review and meta-analysis. Head Neck 42(10):3041–3050PubMedCrossRef
72.
Cengiz AB et al (2021) Comparison of preoperative diagnostic accuracy of fine needle aspiration and core needle biopsy in parotid gland neoplasms. Eur Arch Otorhinolaryngol 278(10):4067–4074PubMedCrossRef
73.
Eom HJ et al (2015) Comparison of fine-needle aspiration and core needle biopsy under ultrasonographic guidance for detecting malignancy and for the tissue-specific diagnosis of salivary gland tumors. AJNR Am J Neuroradiol 36(6):1188–1193PubMedPubMedCentralCrossRef
74.
Kim HJ, Kim JS (2018) Ultrasound-guided core needle biopsy in salivary glands: a meta-analysis. Laryngoscope 128(1):118–125PubMedCrossRef
75.
Cebeci H et al (2020) Evaluation of benign parotid gland tumors with superb microvascular imaging and shear wave elastography. J Ultrason 20(82):e185–e190PubMedPubMedCentralCrossRef
76.
77.
Klotz LV et al (2013) Perfusion characteristics of parotid gland tumors evaluated by contrast-enhanced ultrasound. Eur J Radiol 82(12):2227–2232PubMedCrossRef
78.
Wei X et al (2013) Evaluation of microvascularization in focal salivary gland lesions by contrast-enhanced ultrasonography (CEUS) and Color Doppler sonography. Clin Hemorheol Microcirc 54(3):259–271PubMedCrossRef
79.
Mungai F et al (2021) Imaging biomarkers in the diagnosis of salivary gland tumors: the value of lesion/parenchyma ratio of perfusion-MR pharmacokinetic parameters. Radiol Med 126(10):1345–1355PubMedCrossRef
80.
Zhang MH et al (2021) Differentiating low and high grade mucoepidermoid carcinoma of the salivary glands using CT radiomics. Gland Surg 10(5):1646–1654PubMedPubMedCentralCrossRef
81.
Siebers S et al (2010) Computer aided diagnosis of parotid gland lesions using ultrasonic multi-feature tissue characterization. Ultrasound Med Biol 36(9):1525–1534PubMedCrossRef
82.
Wang Y et al (2022) The diagnostic value of ultrasound-based deep learning in differentiating parotid gland tumors. J Oncol 2022:8192999PubMedPubMedCentral
83.
Zhang G et al (2023) A deep learning model for the differential diagnosis of benign and malignant salivary gland tumors based on ultrasound imaging and clinical data. Quant Imaging Med Surg 13(5):2989–3000PubMedPubMedCentralCrossRef
84.
85.
Zheng Y et al (2022) CT-based radiomics analysis of different machine learning models for differentiating benign and malignant parotid tumors. Eur Radiol 32(10):6953–6964PubMedCrossRef
86.
87.
Matsuo H et al (2020) Diagnostic accuracy of deep-learning with anomaly detection for a small amount of imbalanced data: discriminating malignant parotid tumors in MRI. Sci Rep 10(1):19388PubMedPubMedCentralCrossRef
88.
Gunduz E et al (2022) Deep learning model developed by multiparametric MRI in differential diagnosis of parotid gland tumors. Eur Arch Otorhinolaryngol 279(11):5389–5399PubMedCrossRef
89.
Liu X et al (2023) A deep learning model for classification of parotid neoplasms based on multimodal magnetic resonance image sequences. Laryngoscope 133(2):327–335PubMedCrossRef
90.
Chang YJ et al (2021) Classification of parotid gland tumors by using multimodal MRI and deep learning. NMR Biomed 34(1):e4408PubMedCrossRef
Metadata
Title
Salivary gland pathologies: evolution in classification and association with unique genetic alterations
Authors
Michał Żurek
Łukasz Fus
Kazimierz Niemczyk
Anna Rzepakowska
Publication date
13-07-2023
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 11/2023
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-023-08110-w

Other articles of this Issue 11/2023

European Archives of Oto-Rhino-Laryngology 11/2023 Go to the issue

Rhinology

Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial

Otology

EAONO/JOS classification for acquired cholesteatoma: evaluating the impact of the number of affected sites on treatment and outcomes

Miscellaneous

Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae

Rhinology

Radiopathologic predictors of 1- and 2-year frontal sinusotomy outcomes in a southeast Asian chronic rhinosinusitis population

Head and Neck

A deep learning MRI-based signature may provide risk-stratification strategies for nasopharyngeal carcinoma

Review Article

Evaluation of outcome measures for post-operative dysphagia after anterior cervical discectomy and fusion